



BROKING

 [bajajbroking.in](https://bajajbroking.in) |  | 

# Morning Bell

2 June 2026

## Market Commentary

Indian benchmark indices ended lower for the fourth consecutive session, with the Nifty slipping below the 23,400 mark on June 1 as persistent FII outflows and geopolitical uncertainties continued to weigh on investor sentiment.

- At close, the Sensex declined 508.40 points or 0.68% to 74,267.34, while the Nifty fell 165.15 points or 0.70% to 23,382.60.
- On the sectoral front, most sectors ended in the red, reflecting broad-based selling pressure across the market. Major weakness was observed in Nifty FMCG, PSU Bank, Realty, and Auto, which emerged as the key laggards during the session. However, selective buying interest was visible in Nifty IT, Media, and Metal, which managed to outperform the broader market and provided some cushion to the decline.
- The broader market also witnessed significant profit booking, with the Nifty Midcap 100 index declining 1.45%, while the Nifty Smallcap 100 index fell 0.88%.
- Gift Nifty signals a negative opening for the Indian market. Nifty spot in today's session is likely to trade in the range of 23,100-23,550.

## Global Updates

- Wall Street preserved a highly resilient front to finish its final regular session of the month in positive territory. A softening curve at the long end of sovereign debt markets gave growth indices a highly protective cushion, comfortably shielding mega-cap valuations from intermediate macro crosscurrents.
- The global macro framework is shifting into the new calendar month with highly sensitive geopolitical undertones. While a 60-day tentative truce framework remains actively mediated on the back-channels to secure transit across the Strait of Hormuz, a definitive executive signature has yet to finalize the accord.
- Asian regional layouts are advancing with high confidence this morning, completely looking past localized emerging market volatility to mirror New York's late-week technology expansion:

Indices	CMP	Daily %	YTD %
NIFTY	23383	-0.70	-10.51
BANKNIFTY	53643	-1.10	-9.97
SENSEX	74267	-0.68	-12.85
USDINR	95.00	0.00	14.22
INDIA VIX	16.543	2.21	74.59

Global Indices	CMP	Daily %	YTD %
DOW	51078.9	0.09	6.27
S&P500	7600.0	0.26	11.02
NASDAQ	27086.8	0.42	16.54
NIKKEI	65819.8	-1.67	30.75
HANGSENG	25770	1.46	0.54

Comm & Gsec	CMP	Daily %	YTD %
GOLD (\$)	4514.3	0.18	4.54
BR. CRUDE (\$)	94.5	-0.54	26.15
COPPER (\$)	6.58	0.40	63.81
US 10YR (%)	4.45	-0.13	-2.23

Asian Market updated on 8:00 AM

## Fund flow Activity on NSE BSE & MSEI

Participant	Cash (in Cr)	MTD (in Cr)	YTD (in Cr)
FII	-3911.68	-3911.68	-300626.88
DII	5109.13	5109.13	389446.15


## Key Events

RBI MONETARY POLICY on 05-06-2026

## Stocks in F&O Ban

AMBER, KAYNES

## Position of Market Participants




**Index Highlights (DAILY)**

Index	Futures Price	Change	Change (%)	VWAP	Basis	Volume	Change in OI	OI%	ATM IV's	PCR OI
Nifty	23,462.00	-286.8	-1.2%	23,577.97	79.40	84,714	7,52,505	4.1%	16.8	0.69
Bank Nifty	53,973.00	-787	-1.4%	54,211.51	329.90	34,010	99,150	3.7%	19.0	0.81


Price Rise		OI Gainers				IV Rise		PCR Rise	
Symbol	Price %	Symbol	Price %	Oi %	Longshort	Symbol	IV %	Symbol	Change %
NMDC	4.6%	FINNIFTY	-1.9%	49.4%	Short_Buildup	RADICO	6.6	GODREJCP	0.36
TECHM	4.3%	GVT&D	-7.6%	21.7%	Short_Buildup	SUPREMEIND	4.9	GODFRYPHLP	0.34
NBCC	3.4%	IREDA	-5.5%	16.6%	Short_Buildup	ANGELONE	4.8	SHREECEM	0.25
PERSISTENT	3.1%	COALINDIA	3.1%	8.4%	Long_Buildup	POWERINDIA	4.7	PERSISTENT	0.18
COALINDIA	3.1%	KAYNES	-3.8%	8.0%	Short_Buildup	SUZLON	4.2	FORCEMOT	0.17

Price Fall		OI Losers				IV fall		PCR Fall	
Symbol	Price %	Symbol	Price %	Oi %	Longshort	Symbol	IV %	Symbol	Change %
INOXWIND	-10.2%	HCLTECH	2.1%	-4.9%	Short_Covering	INDIGO	-6.3	NIFTYNXT50	-0.67
GVT&D	-7.6%	LTM	2.5%	-4.0%	Short_Covering	GLENMARK	-4.9	LODHA	-0.39
SUZLON	-5.9%	PNBHOUSING	-3.2%	-3.5%	Long_Unwinding	ASIANPAINT	-3.8	PAGEIND	-0.33
IREDA	-5.5%	NATIONALUM	2.6%	-3.3%	Short_Covering	INOXWIND	-3.7	ANGELONE	-0.32
POWERINDIA	-5.3%	BLUESTARCO	-3.3%	-2.9%	Long_Unwinding	PATANJALI	-2.4	JSWENERGY	-0.29


**Index Future Participant wise OI Change**




**Index Option Participant wise OI Change**




**Participant wise L/S Ratio**



**Future Index Long**



**Future Index Short**



### Nifty Outlook



Index in the daily chart formed a second sizable bearish candlestick pattern with a lower high and a lower low, index in the process closed below last week low 23,484 highlighting continuation of the downward bias.

Going ahead bias continues to remain down and index likely to test last month low of 23262 in the coming sessions. Only a formation of higher high and higher low in the daily chart will signal a pause in the downtrend.


Nifty is approaching the key support area of 23,200-23,000 being the confluence of the lower band of the 8th April bullish gap area, lower band of recent consolidation and the 61.8% retracement of the previous pullback (22,182-24,601).

On the higher side 23,700-23,800 is expected to act as resistance being confluence of Monday's high and 20 days EMA.

### Intraday Support & Resistance

Index	S2	S1	Close	R1	R2
Nifty	23100	23220	23382.60	23480	23550

### Nifty Option Chain



- ❑ With weekly expiry scheduled for tomorrow, Nifty Synthetic Futures are positioned near 23,430, below the crucial support zone, indicating a weak near-term structure.
- ❑ Significant put unwinding above 23,500 and limited put participation at 23,400 suggest that the support base has weakened considerably.
- ❑ A decisive break below 23,400 could accelerate selling pressure and push the index towards the 23,300-23,200 zone.
- ❑ On the upside, call writers continue to dominate at 23,400, 23,500 and 23,600 strikes, creating multiple resistance levels and capping any meaningful recovery.
- ❑ The Max Pain level is positioned at 23,500, making it an important reference point for expiry.
- ❑ A sustained move back above 23,500 is required to negate the current bearish setup and improve the prospects for an upside recovery.

## Bank Nifty Outlook



Index in the daily chart formed a bearish candle with a lower high and a lower low, index in the process closed below last week low 54,116 highlighting continuation of the downward bias.

Index likely to consolidate in the range of 52,500-55,600 only a breakout or breakdown will signal directional moment in the index.


Index has key support placed at 52,700-52,500 being the confluence of the lower band of the 8th April bullish gap area and the 61.8% retracement of the previous pullback (49955-57456).

On the higher side key resistance at 55,600-56,000 levels being the confluence of last week high and 50 days EMA.

## Intraday Support & Resistance

Index	S2	S1	Close	R1	R2
Bank Nifty	52800	53140	53643.10	53930	54300



## Bank Nifty Option Chain



- ❑ Bank Nifty continues to exhibit a corrective bias as option data reflects stronger participation from call writers.
- ❑ Significant call OI addition at 54,000 has established it as a strong resistance zone.
- ❑ Limited put accumulation and the dominance of call writing indicate a bearish conviction at current levels.
- ❑ Failure to reclaim 54,000 could keep the index under pressure and drag it towards the immediate support area of 53,500.
- ❑ A move above 54,000 would likely trigger short covering, paving the way for a recovery towards 54,500.

**News and its impact**

Company/ Industry	News	Impact
<b>VIP INDUSTRIES</b>	The company launches three luggage collections under the "Travel VIP" campaign. The company discontinues sale of products under the "Carlton" brand from today, stating no financial impact and citing compliance with Supreme Court directions.	<b>POSITIVE</b>
<b>ANANT RAJ</b>	The company will invest Rs. 25,000 crore to build a data centre and develop cloud services in Haryana under an MoU with the state.	<b>POSITIVE</b>
<b>NHPC</b>	The government proposes to sell up to 3% stake via OFS, with an option to sell an additional 3%. The offer opens on June 2 for non-retail investors and June 3 for retail investors. The floor price is set at Rs. 71 per share.	<b>NEUTRAL</b>
<b>OLA</b>	The company opens its QIP issue, setting a floor price of Rs. 37.74 per share, with a potential discount of up to 5%.	<b>NEUTRAL</b>
<b>MOIL</b>	The company revises prices of manganese ore and related products, cutting prices of ferro grades by 6%.	<b>NEUTRAL</b>

**Indian ADR % Change**

**Sector**


## Glenmark Pharmaceuticals Q4FY26 Result Update

### Result Update

The company reported quarterly revenue of ₹37.6 billion, registering a healthy 17% year-on-year growth, although it declined 3% sequentially and came in 2% below market expectations. EBITDA stood at ₹7.5 billion, reflecting a robust 43% YoY increase, but softened 12% both on a quarter-on-quarter basis and versus consensus estimates. EBITDA margins expanded significantly by 370 basis points YoY to 20%, highlighting improved operational efficiency, though they contracted 204 basis points sequentially and missed expectations by 232 basis points. Profit after tax came in at ₹3.0 billion, marking an exceptional 6,773% surge compared to the corresponding quarter last year, aided by a low base effect, while declining 25% QoQ and falling 42% short of consensus forecasts.

### Key Management Call Highlights

#### Guidance and Outlook

- ❑ FY27 Revenue Guidance: INR 17,000–18,000 crore (~17–18% growth over FY26).
- ❑ FY27 EBITDA Margin Guidance: 21–22%, factoring in strategic growth investments in India and EMs, and accounting for geopolitical environment and currency headwinds.
- ❑ Capex: FY26 intangibles elevated (~INR 800 crore+) due to one-time in-licensing payments; management expects total capex to normalize to ~INR 900 crore in FY27.
- ❑ Strategic growth investments planned in India and emerging markets in FY27 – details to be disclosed at the upcoming Investor Day.
- ❑ Working capital guidance maintained at sub-115–120 days net working capital.
- ❑ R&D spend expected to remain at 7–8% of sales in FY27.
- ❑ More granular FY27 growth driver details to be shared at the Investor Day (scheduled ~1 week post earnings)

#### India Business

- ❑ India formulations revenue for Q4 FY26: INR 10,000 million vs. INR 9,430 million in Q4 FY25, up 8.2% YoY.
- ❑ Secondary sales growth of 10.3% in Q4 and 13.5% for full-year FY26, meaningfully outpacing IPM (IQVIA) growth of 10.1% in Q4 and 9% for MAT March 2026.

### Key Data

<b>CMP (Rs)</b>	2247
<b>Sector / Industry</b>	Pharmaceuticals
<b>52 week High/Low</b>	2474 / 1448
<b>Market Cap (bn)</b>	634.18
<b>Bloomberg Code</b>	GNP:IN
<b>Face Value (₹)</b>	1.00

### Shareholding %

Particulars	Q2FY26	Q3FY26	Q4FY26
Promoters	46.6	46.7	46.7
FII	20.7	19.2	20.4
DII	18.6	20.1	19.3
Others	14.1	14.0	13.6

# No Promoter Pledge

### Financial Ratios

Ratio	FY24	FY25	FY26
ROCE (%)	-	15.7	16.1
ROE (%)	-	12.5	12.9
PE (%)	-	41.5	44.2
P/B(x)	3.4	4.9	5.9
Debt/Equity	(5.5)	(0.5)	(5.5)
EV/EBITDA	21.4	18.3	22.2

### NIFTY VS GNP:IN

Returns (%)	1M	3M	6M	12M
Nifty 50	(2.6)	(6.5)	(10.1)	(4.7)
GNP	(5.8)	6.5	16.9	51.9

### Financial Metrics

(Rs in mn)

Particulars	Q4FY26	Q4FY25	YoY (%)	Q3FY26	QoQ (%)	Estimates#	Var (%)	FY26	FY27#	FY28#
Revenue	37,602.8	32,201.3	17%	38,880.0	-3%	38,489.0	-2%	1,67,114.0	1,62,446.0	1,80,078.0
EBITDA	7,522.9	5,249.5	43%	8,571.3	-12%	8,593.0	-12%	43,013.1	36,209.0	42,245.0
<b>EBITDA Margin (%)</b>	<b>20.0%</b>	<b>16.3%</b>	<b>370bps</b>	<b>22.0%</b>	<b>-204bps</b>	<b>22.3%</b>	<b>-232bps</b>	<b>25.7%</b>	<b>22.3%</b>	<b>23.5%</b>
Adj. PAT	3,013.2	43.8	6773%	4,032.9	-25%	5,181.0	-42%	13,619.5	22,887.0	27,196.0
<b>PAT Margin (%)</b>	<b>8.0%</b>	<b>0.1%</b>	<b>788bps</b>	<b>10.4%</b>	<b>-236bps</b>	<b>13.5%</b>	<b>-545bps</b>	<b>8.1%</b>	<b>14.1%</b>	<b>15.1%</b>
EPS	10.7	0.2		14.3		19.3		48.3	82.78	98.3

## Glenmark Pharmaceuticals Q4FY26 Result Update

- ❑ Glenmark ranked 13th in India with 2.34% market share; 11 brands in the top-300.
- ❑ Therapeutic area rankings (IQVIA): #2 in Dermatology, #3 in Respiratory, #4 in Cardiac – all segments outperforming except Diabetes.
- ❑ Emerged as the second fastest-growing company among the top-15 pharma companies in FY26 per IQVIA.
- ❑ Key new launches during FY26:
  - ❑ TEVIMBRA and BRUKINSA (Oncology) – launched in Q1 FY26; seeing strong early uptake, expected to meaningfully contribute over the next 2–3 years.
  - ❑ NEBZMARK GFB nebulizer (Respiratory) – world's first fixed-dose triple therapy for COPD (glycopyrronium + formoterol + budesonide); key growth driver in chronic respiratory in FY26.
  - ❑ GLIPIQ (Semaglutide vials and pre-filled pen) – launched in Q4 for Type 2 Diabetes management; CDSCO-approved following multicenter clinical trial; accompanied by patient support program "Sankalp."
- ❑ Jabras (Dermatology) – first-of-its-kind oral advanced systemic treatment; well received by physicians.
- ❑ Diabetes segment weakness identified as the only lagging therapeutic area – attributed to competitive pressure from DAPA going generic (hurting Remogliflozin/SGLT2 franchise) and Sitagliptin going generic (hurting Teneeligliptin). Management expects recovery from Q1 FY27 on the back of GLIPIQ. Consumer care sales: INR 1,265 million in Q4, up ~10% YoY; flagship brands La Shield, Bontress, Aloe Vera, and Episoft recorded double-digit secondary sales growth. Management guiding for 15%+ India business growth in FY27.

### North America Business

- ❑ Q4 FY26 North America revenue: INR 9,248 million vs. INR 7,146 million in Q4 FY25, up 29.4% YoY.
- ❑ Excluding deferred out-licensing income recognition for ISB 2001 (AbbVie deal), core business grew 7.8% YoY in Q4 – indicating underlying US business growth remains modest.
- ❑ Key drag in Q4: Fluticasone MDI 44 mcg and Fluticasone nasal spray OTC were approved by end of March but could not be meaningfully commercialized due to supply chain disruptions, resulting in fixed-cost underabsorption.
- ❑ 4 products launched in Q4; 13 products launched in FY26 (oral solids, injectables, and respiratory mix); 2 ANDAs filed in Q4, 5 total in FY26.
- ❑ Respiratory franchise milestones:
  - ❑ First ANDA approval: Fluticasone MDI 44 mcg (generic to Flovent) – CGT designation as first approved applicant, eligible for 180-day exclusivity upon commercialization.
  - ❑ Approval received for Fluticasone nasal spray OTC.
  - ❑ 3 additional respiratory ANDAs filed during FY26.
  - ❑ Targeting 2–3 respiratory product launches in FY27, including Fluticasone RX, Fluticasone 110 MDI (already filed), and one additional MDI filed.
- ❑ Injectable franchise: ~20 products now commercialized through partners; Monroe facility received EIR (VAI classification) from US FDA post November 2025 inspection – enabling restart of commercial manufacturing, a key enabler for future growth in injectables and institutional business.
- ❑ Ryaltris US commercialization: As of April 2026, Glenmark has taken over end-to-end commercialization of Ryaltris in the US, exiting the Hikma partnership. Management believes direct control will improve execution.
- ❑ Sole FTF pipeline for FY27: Gabapentin Enacarbil and Axitinib – both expected to launch in Q3/Q4 FY27, providing exclusivity-driven revenue uplift.
- ❑ Management expects the US business to be a major growth driver in FY27, driven by: full-year traction from Fluticasone products, additional respiratory launches, sole FTF exclusivities, and Ryaltris under own commercialization.

### Europe Business

- ❑ Q4 FY26 European revenue: INR 8,907 million vs. INR 7,335 million in Q4 FY25, up 21.4% YoY.
- ❑ Growth was broad-based: Central & Eastern Europe (CE region) delivered double-digit growth across all key markets; Western Europe (notably Germany and Netherlands) also saw good momentum.
- ❑ Branded business, particularly in respiratory and dermatology, driving the outperformance.
- ❑ Ryaltris / Ieltris continues to gain market share across all launched markets (via Glenmark and partner Menarini).
- ❑ Winlevi (acne treatment): Launched in the UK in Q1 FY26; MA approval received for licensed European markets – commercial rollout planned in FY27.
- ❑ Glenmark plans to expand its commercial respiratory portfolio in Europe through 2–3 additional product launches in FY27.
- ❑ Management guidance for Europe: High single-digit growth in FY27, making it the more conservative market vs. India, US, and EMs.

### Emerging Markets Business

- ❑ Q4 FY26 Emerging Markets revenue: INR 8,979 million vs. INR 7,898 million in Q4 FY25, up 13.7% YoY.
- ❑ Russia: Secondary sales growth of 11% per IQVIA March MAT 2026; ranked 8th in dermatology in Russia.
- ❑ LATAM and MENA: Lenmox recorded good secondary sales growth; multiple respiratory products launched in FY26, aiding performance.
- ❑ APAC: Double-digit secondary sales growth in Malaysia and Australia; strong market share in dermatology and respiratory.

## Glenmark Pharmaceuticals Q4FY26 Result Update

- ❑ Ryaltris continues to be the leading nasal spray in allergic rhinitis across most launched emerging markets. Launched in China (partner: Grand Pharma) and Thailand (partner: Organon) in Q4 FY26 – management expecting significant growth uplift from these new markets.
- ❑ Brazil Ryaltris launch planned in FY27 – described as a "big commercial launch."
- ❑ Collections in MENA region were delayed in Q4 due to regional conflict – expected to normalize.

### Global Innovation Portfolio (Ryaltris / Ieltris)

- ❑ Commercialized in 55 markets as of March 2026; expected launches in 8–10 additional markets over the next few quarters.
- ❑ Full-year FY26 brand revenues crossed \$100 million with ~50% secondary sales growth across commercial markets.
- ❑ Management guiding for 30–40% annual growth for Ryaltris going forward, driven by ongoing market launches, China and Brazil ramp-up, and US direct commercialization.
- ❑ Product still in launch phase in many markets – significant runway ahead.

### IGI (Innovation Pipeline) – Strategic Highlight

- ❑ ISB 2001 (AbbVie deal): The landmark licensing deal with AbbVie for \$700 million upfront and up to \$1.925 billion total deal value (including tiered double-digit royalties) remains the defining event of FY26. Revenue recognition ongoing at \$70 million per year (\$17.5 million/quarter); \$35 million recognized in H2 FY26.
- ❑ Phase 1 dose expansion enrollment is progressing rapidly; efficacy and safety data described as "promising and consistent" with prior disclosures.
- ❑ ISB 2301: Clinical candidate selected; IND submission targeted by end of calendar year 2026. Management described this as potentially a "world-class asset."
- ❑ ISB 2302 and ISB 2501: Two additional pipeline assets disclosed – described as "very promising."
- ❑ ISB 880 (LAD191): Licensed to Almirall; Phase 2 study in Hidradenitis Suppurativa ongoing with active patient recruitment. Almirall also plans to initiate proof-of-concept for an additional inflammatory skin disease indication. Also partnered with Astria/BioCryst.
- ❑ IGI Leadership Change: Cyril Konto (former head) departed ~6–8 months ago. Lida Pacaud, previously Chief Medical Officer at IGI (3–4 years tenure), has been appointed the new CEO of IGI.

### Innovative Oncology Portfolio – India & Emerging Markets

- ❑ CBEIZHANYO (Envafolelimab): MA applications filed in 24 markets as of March 2026; first commercial launch expected in FY28. Early access / named patient programs initiated in 7 markets (Kenya, Mauritius, Uganda, etc.).
- ❑ Trastuzumab Rezetecan (Hengrui): HER2-targeting ADC licensed in Q2 FY26; first wave of MA applications expected by end of H1 FY27. Approved in China for HER2 NSCLC and HER2 breast cancer; BLA also filed in China for HER2-advanced colorectal cancer.
- ❑ Aumolertinib (Hansoh): Third-gen EGFR TKI for NSCLC; licensed in Q3 FY26 for India and most emerging markets. Already approved in UK (June 2025) and EU (February 2026) for first-line advanced/metastatic NSCLC with active EGFR mutations; marketed across 5 indications in China. MA applications submitted in multiple markets; first commercial launch anticipated H2 FY27.
- ❑ Anlotinib: Launch expected in FY27 in India/EMs.
- ❑ Management views the innovative oncology pipeline as a "significant contributor" over the next 5–7 years, with very high expected growth rates from India and EMs.

### Key Risks and Challenges

- ❑ US execution risk: Revenue guidance implies very high US growth (~40–45% as estimated by analysts), which depends on timely launches of respiratory products, FTF exclusivities materializing, and Ryaltris ramping under direct commercialization – all carrying execution uncertainty.
- ❑ Geopolitical headwinds: Continued supply chain and distribution cost pressures, especially in global markets; MENA collections delayed due to regional conflict.
- ❑ Currency volatility: Sharp currency movements impacting both reported revenues and receivables; acknowledged as an ongoing risk.
- ❑ Diabetes franchise weakness: Structural pressure from key molecules losing exclusivity (Remogliflozin vs. DAPA generic; Teneigliptin vs. Sitagliptin generic); expected recovery is dependent on GLIPIQ ramp-up.
- ❑ Litigation: One or two outstanding US legal cases remain; management expects resolution over the next few years. Substantially de-risked but not fully closed.
- ❑ Disclosure quality: An analyst on the call flagged inconsistent quarterly disclosures on key metrics (net debt, gross debt, capex, R&D) – management acknowledged and committed to review, suggesting room for investor relations improvement.
- ❑ Receivables build-up: Sharp increase in receivables warrants monitoring, even if management attributes it to identifiable and reversible causes.

# WEEKLY ECONOMIC CALENDAR

▶▶ 31 May - 5 June 2026 ◀◀

## United States

**Event:** 1 June

- ▶ S&P Global US Manufacturing PMI
- ▶ ISM Manufacturing

**Event:** 3 June

- ▶ ADP Employment Change
- ▶ S&P Global US Services PMI
- ▶ S&P Global US Composite PMI

**Event:** 3 June

- ▶ Initial Jobless Claims

**Event:** 5 June

- ▶ Change In Nonfarm Payrolls
- ▶ Unemployment Rate

## India

**Event:** 1 June

- ▶ HSBC India PMI Mfg
- ▶ Industrial Production YoY

**Event:** 3 June

- ▶ HSBC India PMI Composite
- ▶ HSBC India PMI Services

**Event:** 5 June

- ▶ RBI Repurchase Rate
- ▶ GDP YoY

## China

**Event:** 31 May

- ▶ Manufacturing PMI
- ▶ Non-Manufacturing PMI

**Event:** 1 June

- ▶ RatingDog China PMI Mfg

## Nifty 50 stocks – Support & Resistance

Stock Name	Support 2	Support 1	Close	Resistance 1	Resistance 2
ADANIANT	2854.13	2881.77	2909.40	2946.37	2983.33
ADANIPTS	1753.90	1768.70	1783.50	1806.60	1829.70
APOLLOHOSP	7977.83	8043.17	8108.50	8211.67	8314.83
ASIANPAINT	2527.20	2579.80	2632.40	2731.90	2831.40
AXISBANK	1252.50	1264.20	1275.90	1290.40	1304.90
BAJAJ-AUTO	10166.00	10271.00	10376.00	10550.00	10724.00
BAJAJFINSV	1723.83	1741.37	1758.90	1791.07	1823.23
BAJFINANCE	868.35	878.70	889.05	908.70	928.35
BEL	399.60	403.40	407.20	412.35	417.50
BHARTIARTL	1780.73	1795.67	1810.60	1833.77	1856.93
CIPLA	1369.03	1379.67	1390.30	1407.27	1424.23
COALINDIA	448.27	460.43	472.60	480.88	489.17
DRREDDY	1263.47	1276.93	1290.40	1311.73	1333.07
EICHERMOT	6965.83	7033.17	7100.50	7204.17	7307.83
ETERNAL	243.47	245.78	248.10	252.13	256.17
GRASIM	3041.27	3071.93	3102.60	3145.63	3188.67
HCLTECH	1176.63	1185.87	1195.10	1208.57	1222.03
HDFCBANK	731.60	737.15	742.70	750.30	757.90
HDFCLIFE	572.88	579.72	586.55	598.62	610.68
HINDALCO	1116.70	1129.00	1141.30	1151.80	1162.30
HINDUNILVR	2023.50	2053.90	2084.30	2141.10	2197.90
ICICIBANK	1219.83	1229.77	1239.70	1255.77	1271.83
INDIGO	4322.90	4388.10	4453.30	4576.20	4699.10
INFY	1154.43	1178.47	1202.50	1221.77	1241.03
ITC	271.92	275.78	279.65	286.03	292.42
JIOFIN	230.25	232.60	234.95	239.00	243.05
JSWSTEEL	1269.27	1284.33	1299.40	1309.63	1319.87
KOTAKBANK	368.67	373.03	377.40	384.38	391.37
LT	3935.87	3973.33	4010.80	4077.03	4143.27
M&M	2892.13	2931.17	2970.20	3039.07	3107.93
MARUTI	12688.00	12817.00	12946.00	13171.00	13396.00
MAXHEALTH	913.08	925.77	938.45	961.57	984.68
NESTLEIND	1358.67	1375.23	1391.80	1421.63	1451.47
NTPC	368.90	373.80	378.70	386.30	393.90
ONGC	260.23	262.27	264.30	267.32	270.33
POWERGRID	280.08	283.12	286.15	290.77	295.38
RELIANCE	1307.67	1313.83	1320.00	1330.83	1341.67
SBILIFE	1775.63	1794.07	1812.50	1838.67	1864.83
SBIN	938.00	946.05	954.10	966.20	978.30
SHRIRAMFIN	892.32	905.68	919.05	943.13	967.22
SUNPHARMA	1760.23	1778.37	1796.50	1813.37	1830.23
TATACONSUM	1113.30	1128.30	1143.30	1170.40	1197.50
TATASTEEL	204.59	207.58	210.57	212.48	214.39
TCS	2249.13	2273.27	2297.40	2328.27	2359.13
TECHM	1466.33	1504.77	1543.20	1572.07	1600.93
TITAN	3947.53	3986.07	4024.60	4084.07	4143.53
TMPV	374.20	379.55	384.90	394.55	404.20
TRENT	4072.23	4114.77	4157.30	4227.97	4298.63
ULTRACEMCO	10978.67	11105.33	11232.00	11464.33	11696.67
WIPRO	203.77	205.09	206.41	207.74	209.07



## Disclaimer

**Bajaj Financial Securities Limited (BFSL)** is a subsidiary of Bajaj Finance Limited (BFL) and a step-down subsidiary of Bajaj Finserv Limited. The parent entities of BFSL are public listed companies and have various subsidiaries engaged in the business of NBFC, Housing Finance, Insurance, AMC etc. BFSL is *inter alia* SEBI registered Stock-Broker, Depository Participant and distributor of financial products.

**Analyst Certification:** We/I, Sumit Singhania, Pradeep Kasat, Anand Shendge, Pabitra Mukherjee, Vikas Vyas, Nisarg Shah, Shashwat Singh, Raunaq Murarka authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### Registration Details

Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. | Corp. Office: Bajaj Financial Securities Ltd., 1st Floor, Mantri IT Park, Tower B, Unit No 9, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O (Member ID: 6706) | NSE Cash/F&O (Member ID: 90177) | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 | AMFI Registration No.: ARN – 163403 | Research Analyst Regn: INH00010043.

Compliance Officer: Mr. Boudhayan Ghosh (For Broking/DP/Research) email@ compliance\_sec@bajajbroking.in | Contact No.: 020-4857 4486 |

Disclaimers & Disclosures- SEBI Research Analysts Regulations, 2014

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Kindly refer to <https://www.bajajbroking.in/disclaimer> for detailed disclaimer and risk factors.

There were no instances of non-compliance by BFSL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last 3 years. The information/opinion in this report are as on date and there can be no assurance that future results or events will be consistent with this information/opinion. This report is subject to change without any notice. This report and information are strictly confidential and is being furnished to you solely for your information and may not be altered in any way, transmitted to, copied or distributed, in part or in whole to any other person or to media or reproduced in any form without prior written consent of BFSL. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any jurisdiction including but not limited to USA and Canada, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject BFSL and associates / group companies to any registration or licensing requirements within such jurisdiction.

BFSL, its directors, officers, agents, representative, associates / group companies shall not be in any way responsible for any loss or damage (direct, indirect, special or consequential) that may arise to any person from any inadvertent error, use of this report/information contained in this report. The report is based on information obtained in good faith from public sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness is guaranteed. This should not be construed as invitation or solicitation to do business with BFSL.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance.

The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. BFSL offers its research services to clients as well as our prospects, though disseminated, to all customers simultaneously, not all customers may receive this report at the same time. BFSL will not treat recipients as customers by virtue of their receiving this report.

BFSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

BFSL or its associates may have received compensation from the subject company in the past 12 months in respect of managing/co-managed public offering of securities, for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. BFSL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. BFSL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.

Research analyst or his/her relative or BFSL's associates may have financial interest in the subject company. BFSL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Research analyst has served as an officer, director or employee of subject Company: No | Bajaj Broking has financial interest in the subject companies: No | Bajaj Broking's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report. Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No | Bajaj Broking has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No | Subject company may have been client during twelve months preceding the date of distribution of the research report.

A graph of daily closing prices of the securities is also available at [www.nseindia.com](http://www.nseindia.com). Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."

**For more queries reach out to :** Name - Bajaj Broking Research Team | Email Id - researchdesk@bajajbroking.in

<b>Research Analysts :</b>	<b>Sumit Singhania</b> (Research Head)	<b>Pradeep Kasat</b> (Sr VP Technical Analyst)	<b>Anand Shendge</b> (DVP Derivative Analyst)	<b>Pabitra Mukherjee</b> (DVP Technical Analyst)
	<b>Vikas Vyas</b> (Derivative Analyst)	<b>Raunaq Murarka</b> (Derivatives Analyst)	<b>Nisarg Shah</b> (Fundamental Analyst)	<b>Shashwat Singh</b> (Fundamental Analyst)